Entrepreneur, Angel Investor, and Board Member Raju Reddy discusses his AI investment thesis.
Entrepreneur, Angel Investor, and Board Member Raju Reddy discusses his AI investment thesis.
As founders, we often focus on product development but overlook the critical factor that can make or break our chances of securing funding: Velocity. Potential for Velocity in the early stages. Evidence of Velocity in the later stages.
Will you be seeking investor introductions for your startup in 2025? Top VC funds operate in the 98% rejection rate zone. Let’s avoid the pitfalls of wasting time and money without achieving results. If you are looking for investor introductions, you have to be READY.
Please post this on your wall in 2025: “Startups: Do NOT Go to VCs as Beggars. Go as Kings.” This is the 1Mby1M mantra and it works. Over 99% of founders chase funding before they are fundable.
As you know, I categorically support bootstrapped entrepreneurs. There are numerous startups now that have achieved some revenue without any external funding. However, it has taken time. Sometimes, it has taken 5-7 years to get there. VCs, however, are looking for velocity.Their goal is to achieve $100M in 5-7 years.
Sramana Mitra: What is going on in the thought process of the venture capital community vis-a-vis healthcare drug discovery and general AI in the healthcare and life sciences area? When the lean startup movement came about, SaaS was the dominant field in which VCs were investing for maybe even 15 years, the venture capital industry
Sramana Mitra: So now, let’s switch a little bit to surgery. Now comes the domain of robotic surgery, which is again, a very, very important and very promising area of AI application. It could really change human’s level of access to healthcare in a very big way. However, from a startup point of view, building